Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Over 15 pharmaceutical companies are actively developing more than 20 pipeline drugs for synovial sarcoma treatment, with promising therapies in various clinical trial stages. Key players including Takara Bio, Immatics, Moderna, Adaptimmune, and Zelluna are advancing innovative approaches such as TCR-T therapies and bispecific antibodies to address the significant unmet medical need in this rare cancer indication.

05/28/2026, 1:00 PM • GlobeNewswire

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.

05/27/2026, 1:00 PM • GlobeNewswire

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight

The peripheral T-cell lymphoma (PTCL) treatment market is projected to grow at a 7% CAGR through 2036, driven by increasing disease incidence and expanding patient populations. The market was valued at USD 800 million in 2025, with the US accounting for 68% of the market. Multiple emerging therapies from major pharmaceutical companies are expected to transform the treatment landscape, with ADCETRIS currently holding the largest market share at over USD 300 million.

04/27/2026, 1:00 PM • GlobeNewswire

AstraZeneca Responds With Data After FDA Delays Lupus Drug Shot

AstraZeneca received a Complete Response Letter from the FDA regarding its Saphnelo subcutaneous formulation for lupus treatment and has submitted requested additional information. An FDA decision is expected in H1 2026. Additionally, AstraZeneca and Daiichi Sankyo's Datroway received Priority Review for triple-negative breast cancer, with an FDA decision anticipated in Q2 2026.

02/03/2026, 6:55 AM • Benzinga

AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

AstraZeneca announced it will delist its American Depositary Shares from Nasdaq and transition to a direct listing on the NYSE, effective January 30, 2026, to harmonize its global listing structure and reach broader investors. The company also received validation from the European Medicines Agency for its cancer drug Enhertu in combination with pertuzumab. AstraZeneca shares fell 3.55% on the news.

01/20/2026, 11:47 AM • Benzinga

Tenosynovial Giant Cell Tumors Market to Show Significant Growth by 2034 as CSF1R-Targeted Therapies Drive the Next Wave | DelveInsight

The tenosynovial giant cell tumors (TGCT) market is expected to grow significantly through 2034, driven by rising awareness, improved diagnostics, and the increasing adoption of CSF1R-targeted therapies. The market is projected to expand from over 630,000 prevalent cases in 2024, with the US representing the largest market. Key emerging therapies include emactuzumab (SynOx Therapeutics), pimicotinib (Abbisko Therapeutics/Merck), and AMB-051 (AmMax Bio), which aim to provide non-surgical treatment options for diffuse and recurrent TGCT cases.

01/19/2026, 1:00 PM • GlobeNewswire

AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial

AstraZeneca announced that its LATIFY Phase 3 trial of ceralasertib combined with Imfinzi failed to meet the primary endpoint of overall survival versus docetaxel in advanced lung cancer patients. However, the company received positive news with Enhertu securing FDA Breakthrough Therapy Designation for early breast cancer, and announced a $100 million collaboration with Jacobio Pharma for a Pan-KRAS inhibitor with up to $1.915 billion in milestone payments.

12/22/2025, 12:19 PM • Benzinga

Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million

Allegro NV and American Regent have signed an exclusive licensing agreement for Synoglide™, a novel osteoarthritis treatment for horses, with potential milestone payments up to $35 million. The deal allows American Regent to commercialize the treatment in the veterinary market while Allegro retains human application rights.

11/25/2025, 2:30 AM • GlobeNewswire

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy

AstraZeneca and Daiichi Sankyo reported positive Phase 3 trial results for Datroway, a breast cancer drug showing significant survival improvement over standard chemotherapy for triple-negative breast cancer patients.

10/06/2025, 8:50 AM • Benzinga

Trump’s Tariff Gambit: Pharma in the Crosshairs and Global Markets on Edge

President Trump announced a 100% tariff on branded and patented pharmaceutical products starting October 1, 2025, causing significant market disruption and raising concerns about global pharmaceutical supply chains and trade policy.

09/26/2025, 2:54 AM • Investing

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Esperion reported Q2 2025 total revenue growth of 12% to $82.4 million, with U.S. net product revenue increasing 42% year-over-year. The company achieved its first quarter of operating income and expects sustainable profitability starting in Q1 2026, driven by strong commercial execution and cardiovascular disease prevention therapies.

08/05/2025, 6:00 AM • GlobeNewswire

Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight

A comprehensive report reveals over 50 companies are developing 55+ pipeline drugs for endometrial cancer, focusing on advanced therapies and improving treatment paradigms for postmenopausal women.

07/15/2025, 1:00 PM • GlobeNewswire